Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

被引：0
|
作者：
Qiu, Lugui [1 ,2 ]
Fu, Weijun [3 ]
Xia, Zhongjun [4 ]
Fu, Zhengzheng [5 ]
Chen, Wenming [6 ]
Chang, Chunkang [7 ]
Fang, Baijun [8 ]
An, Gang [1 ,2 ]
Wei, Yongqiang [9 ]
Cai, Zhen [10 ]
Gao, Sujun [11 ]
Weng, Jianyu [12 ]
Chen, Lijuan [13 ]
Jing, Hongmei [14 ]
Fei, Li [15 ]
Liu, Zhuogang [16 ]
Chen, Xiequn [17 ]
Liu, Jing [18 ]
Yu, Yang [19 ]
Wang, Aihua [19 ]
Yang, Yijun [19 ]
Yu, Zhinuan [19 ]
Lynch, Kevin [19 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China
[3] Shanghai Chang Zheng Hosp, Dept Hematol, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China
[4] Sun Yat Sen Univ, Dept Hematol Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[5] Soochow Univ, Jiangsu Inst Hematol, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China
[6] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
[7] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai, Peoples R China
[8] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[9] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[10] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr,Dept Hematol, Hangzhou, Zhejiang, Peoples R China
[11] Jilin Univ, Hosp 1, Dept Hematol, Changchun, Peoples R China
[12] Guangdong Gen Hosp, Guangzhou, Peoples R China
[13] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China
[14] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[15] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[16] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China
[17] Air Force Med Univ, Xijing Hosp, Xian, Peoples R China
[18] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China
[19] Antengene Therapeut Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145282
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4770
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Salcedo, Meghan
    Lendvai, Nikoletta
    Mastey, Donna
    Schlossman, Julia
    Hultcrantz, Malin
    Korde, Neha
    Mailankody, Sham
    Lesokhin, Alexander
    Hassoun, Hani
    Smith, Eric
    Shah, Urvi
    Diab, Victoria
    Werner, Kelly
    Landau, Heather
    Lahoud, Oscar
    Drullinsky, Pamela
    Shah, Gunjan
    Chung, David
    Scordo, Michael
    Giralt, Sergio
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (03): : 198 - 200
  • [32] Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis
    Zhou, Dao-Bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    BLOOD, 2013, 122 (21)
  • [33] OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY
    Palumbo, A.
    Moreau, P.
    Dimopoulos, M. A.
    Corradini, P.
    Cavo, M.
    Delforge, M.
    Weisel, K. C.
    Goldschmidt, H.
    Petrini, M.
    Kaiser, M. F.
    Slaughter, A.
    Simcock, M.
    Herring, J.
    Peluso, T.
    Sternas, L.
    Zaki, M.
    Ocio, E. M.
    HAEMATOLOGICA, 2015, 100 : 82 - 83
  • [34] Phase 2 Search Study:XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Song, Yuqin
    Cai, Qingqing
    Zhang, Qingyuan
    Sun, Xiuhua
    Yang, Haiyan
    Yao, Zhihua
    Zou, Liqun
    Zhang, Liling
    Cao, Junning
    Wang, Tingyu
    Li, Lanfang
    Liu, Yao
    Jing, Hongmei
    Gao, Sujun
    Ding, Kaiyang
    Liu, Bingshan
    Zhao, Jun
    Zhu, Jun
    BLOOD, 2023, 142
  • [35] A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE
    Palumbo, A.
    Dimopoulos, M. A.
    Richardson, P. G.
    Siegel, D. S.
    Cavo, M.
    Corradini, P.
    Weisel, K. C.
    Delforge, M.
    Chen, C.
    Goldschmidt, H.
    Jagannath, S.
    Lockhorst, H. M.
    Moreau, P.
    Plesner, T.
    Sternas, L.
    Peluso, T.
    Hong, K.
    Herring, J.
    Yu, X.
    Zaki, M. H.
    San Miguel, J.
    HAEMATOLOGICA, 2016, 101 : 535 - 536
  • [36] Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Shah, Jatin J.
    Feng, Lei
    Thomas, Sheeba K.
    Weber, Donna
    Wang, Michael
    Manasanch, Elisabet E.
    Mendoza, Kathleen
    Orlowski, Robert Z.
    BLOOD, 2015, 126 (23)
  • [37] Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis
    Weisel, Katja
    Dimopoulos, Meletios Athanasios
    Van de Donk, Niels
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Kueenburg, Elisabeth
    Collins, Shona
    Lersch, Frederik
    Rosettani, Barbara
    Bacon, Pamela
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E145 - E145
  • [38] Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
    Martin, Thomas G.
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in the MM-003 trial.
    Weisel, Katja
    Moreau, Philippe
    Gibson, Craig J.
    Song, Kevin W.
    Saunders, Owain
    Sternas, Lars Axel
    Hong, Kevin
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
    Ocio, E. M.
    Shah, J.
    Jagannath, S.
    Mateos, M-V
    Palumbo, A.
    Kher, U.
    Marinello, P.
    San Miguel, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345